Followers | 184 |
Posts | 25241 |
Boards Moderated | 14 |
Alias Born | 04/03/2002 |
Wednesday, September 15, 2021 3:13:34 PM
TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Monday, September 20, 2021 at 1:15pm Eastern Time.
To access a live webcast or replay of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at http://www.traconpharma.com.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at http://www.traconpharma.com.
Company Contact:
Investor Contact:
Mark Wiggins
Brian Ritchie
Chief Business Officer
LifeSci Advisors LLC
(858) 251-3492
(212) 915-2578
mwiggins@traconpharma.com
britchie@lifesciadvisors.com
Recent TCON News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/30/2024 09:05:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/30/2024 09:00:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 09:00:18 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/09/2024 09:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:52:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 09:00:11 PM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM